Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma

Fan, 2012, Cholangiocarcinomas can originate from hepatocytes in mice, J Clin Invest, 122, 2911, 10.1172/JCI63212

Sekiya, 2012, Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes, J Clin Invest, 122, 3914, 10.1172/JCI63065

Wistuba, 2004, Gallbladder cancer: lessons from a rare tumour, Nat Rev Cancer, 4, 695, 10.1038/nrc1429

Blechacz, 2011, Clinical diagnosis and staging of cholangiocarcinoma, Nat Rev Gastroenterol Hepatol, 8, 512, 10.1038/nrgastro.2011.131

Yang, 2012, Biliary tract cancers in Olmsted County, Minnesota, 1976–2008, Am J Gastroenterol, 107, 1256, 10.1038/ajg.2012.173

Razumilava, 2013, Classification, diagnosis, and management of cholangiocarcinoma, Clin Gastroenterol Hepatol, 11, 13, 10.1016/j.cgh.2012.09.009

Guyatt, 2008, Going from evidence to recommendations, BMJ, 336, 1049, 10.1136/bmj.39493.646875.AE

Bragazzi, 2012, Cholangiocarcinoma: epidemiology and risk factors, Translational Gastrointestinal Cancer, 1, 21

Khan, 2008, Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma, HPB (Oxford), 10, 77, 10.1080/13651820801992641

Shaib, 2004, The epidemiology of cholangiocarcinoma, Semin Liver Dis, 24, 115, 10.1055/s-2004-828889

Shaib, 2004, Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?, J Hepatol, 40, 472, 10.1016/j.jhep.2003.11.030

Taylor-Robinson, 2001, Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998, Gut, 48, 816, 10.1136/gut.48.6.816

Patel, 2001, Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States, Hepatology, 33, 1353, 10.1053/jhep.2001.25087

West, 2006, Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001, Br J Cancer, 94, 1751, 10.1038/sj.bjc.6603127

Alvaro, 2010, Descriptive epidemiology of cholangiocarcinoma in Italy, Dig Liver Dis, 42, 490, 10.1016/j.dld.2009.10.009

von Hahn, 2011, Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany, Scand J Gastroenterol, 46, 1092, 10.3109/00365521.2011.589472

Shin, 2010, Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea, J Korean Med Sci, 25, 1011, 10.3346/jkms.2010.25.7.1011

Khan, 2002, Changing international trends in mortality rates for liver, biliary and pancreatic tumours, J Hepatol, 37, 806, 10.1016/S0168-8278(02)00297-0

Patel, 2002, Worldwide trends in mortality from biliary tract malignancies, BMC Cancer, 2, 10, 10.1186/1471-2407-2-10

Jepsen, 2007, Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002, J Natl Cancer Inst, 99, 895, 10.1093/jnci/djk201

Tyson, 2011, Risk factors for cholangiocarcinoma, Hepatology, 54, 173, 10.1002/hep.24351

McLean, 2006, Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States, Liver Int, 26, 1047, 10.1111/j.1478-3231.2006.01350.x

McGlynn, 2006, A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States, Cancer Epidemiol Biomarkers Prev, 15, 1198, 10.1158/1055-9965.EPI-05-0811

Khan, 2012, Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?, J Hepatol, 56, 848, 10.1016/j.jhep.2011.11.015

de Martel, 2010, Cholangiocarcinoma: descriptive epidemiology and risk factors, Gastroenterol Clin Biol, 34, 173, 10.1016/j.gcb.2010.01.008

International classification of diseases for oncology (ICD-O). In: Organisation GSWH; 2000.

Malhi, 2006, Cholangiocarcinoma: modern advances in understanding a deadly old disease, J Hepatol, 45, 856, 10.1016/j.jhep.2006.09.001

Deoliveira, 2011, New staging system and a registry for perihilar cholangiocarcinoma, Hepatology, 53, 1363, 10.1002/hep.24227

Welzel, 2006, Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States, J Natl Cancer Inst, 98, 873, 10.1093/jnci/djj234

Shin, 2010, Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma–focus on East and South-Eastern Asia, Asian Pac J Cancer Prev, 11, 1159

Nakeeb, 1996, Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors, Ann Surg, 224, 463, 10.1097/00000658-199610000-00005

DeOliveira, 2007, Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution, Ann Surg, 245, 755, 10.1097/01.sla.0000251366.62632.d3

Khan, 2005, Cholangiocarcinoma, Lancet, 366, 1303, 10.1016/S0140-6736(05)67530-7

Palmer, 2012, Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma, J Hepatol, 57, 69, 10.1016/j.jhep.2012.02.022

Kaewpitoon, 2008, Opisthorchis viverrini: the carcinogenic human liver fluke, World J Gastroenterol, 14, 666, 10.3748/wjg.14.666

Shin, 1996, Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea, Int J Epidemiol, 25, 933, 10.1093/ije/25.5.933

Honjo, 2005, Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand, Int J Cancer, 117, 854, 10.1002/ijc.21146

Sawanyawisuth, 2009, Genes and cholangiocarcinoma, Southeast Asian J Trop Med Public Health, 40, 701

Soreide, 2004, Bile duct cysts in adults, Br J Surg, 91, 1538, 10.1002/bjs.4815

Blechacz, 2008, Cholangiocarcinoma, Clin Liver Dis, 12, 131, 10.1016/j.cld.2007.11.003

Mabrut, 2010, Management of congenital bile duct cysts, Dig Surg, 27, 12, 10.1159/000268109

Edil, 2008, Choledochal cyst disease in children and adults: a 30-year single-institution experience, J Am Coll Surg, 206, 1000, 10.1016/j.jamcollsurg.2007.12.045

Lee, 2008, Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study, Am J Gastroenterol, 103, 1716, 10.1111/j.1572-0241.2008.01796.x

Welzel, 2007, Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study, Int J Cancer, 120, 638, 10.1002/ijc.22283

Zhou, 2008, Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China, World J Gastroenterol, 14, 632, 10.3748/wjg.14.632

Donato, 2001, Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy, Cancer Causes Control, 12, 959, 10.1023/A:1013747228572

Liu, 2011, Risk factors of intrahepatic cholangiocarcinoma in patients with hepatolithiasis: a case-control study, Hepatobiliary Pancreat Dis Int, 10, 626, 10.1016/S1499-3872(11)60106-9

Shaib, 2005, Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study, Gastroenterology, 128, 620, 10.1053/j.gastro.2004.12.048

Sorensen, 1998, Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark, Hepatology, 28, 921, 10.1002/hep.510280404

Yamamoto, 2004, Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma, Cancer Sci, 95, 592, 10.1111/j.1349-7006.2004.tb02492.x

El-Serag, 2009, Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans, Hepatology, 49, 116, 10.1002/hep.22606

Lee, 2009, Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer, Am J Clin Oncol, 32, 348, 10.1097/COC.0b013e31818c08ff

Shaib, 2007, Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study, Am J Gastroenterol, 102, 1016, 10.1111/j.1572-0241.2007.01104.x

Lee, 2009, Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma, Br J Cancer, 100, 1765, 10.1038/sj.bjc.6605063

Peng, 2011, Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: a possible role of hepatitis B virus, Ann Surg Oncol, 18, 1258, 10.1245/s10434-010-1458-5

Grainge, 2009, The antecedents of biliary cancer: a primary care case-control study in the United Kingdom, Br J Cancer, 100, 178, 10.1038/sj.bjc.6604765

Welzel, 2011, Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database, Hepatology, 54, 463, 10.1002/hep.24397

Sia, 2013, Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes, Gastroenterology, 144, 829, 10.1053/j.gastro.2013.01.001

Sia, 2013, Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies, Oncogene, 32, 4861, 10.1038/onc.2012.617

Andersen, 2012, Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors, Gastroenterology, 142, e1015, 10.1053/j.gastro.2011.12.005

Andersen, 2012, Genetic profiling of intrahepatic cholangiocarcinoma, Curr Opin Gastroenterol, 28, 266, 10.1097/MOG.0b013e3283523c7e

Woo, 2010, Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma, Cancer Res, 70, 3034, 10.1158/0008-5472.CAN-09-2823

Oishi, 2012, Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma, Hepatology, 56, 1792, 10.1002/hep.25890

Chiang, 2008, Focal gains of VEGFA and molecular classification of hepatocellular carcinoma, Cancer Res, 68, 6779, 10.1158/0008-5472.CAN-08-0742

Tannapfel, 2000, Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver, Gut, 47, 721, 10.1136/gut.47.5.721

Voss, 2013, Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions, Hum Pathol, 44, 1216, 10.1016/j.humpath.2012.11.006

O’Dell, 2012, Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma, Cancer Res, 72, 1557, 10.1158/0008-5472.CAN-11-3596

Hezel, 2010, Genetics of biliary tract cancers and emerging targeted therapies, J Clin Oncol, 28, 3531, 10.1200/JCO.2009.27.4787

Farazi, 2006, Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice, Cancer Res, 66, 6622, 10.1158/0008-5472.CAN-05-4609

Tannapfel, 2003, Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma, Gut, 52, 706, 10.1136/gut.52.5.706

Borger, 2012, Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping, Oncologist, 17, 72, 10.1634/theoncologist.2011-0386

Wang, 2013, Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas, Oncogene, 32, 3091, 10.1038/onc.2012.315

Ong, 2012, Exome sequencing of liver fluke-associated cholangiocarcinoma, Nat Genet, 44, 690, 10.1038/ng.2273

Koo, 2001, Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma, Cancer Genet Cytogenet, 130, 22, 10.1016/S0165-4608(01)00460-5

Wong, 2002, Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma, J Hepatol, 37, 633, 10.1016/S0168-8278(02)00269-6

Uhm, 2005, Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization, Cancer Genet Cytogenet, 157, 37, 10.1016/j.cancergencyto.2004.05.007

Homayounfar, 2009, Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization, Hum Pathol, 40, 834, 10.1016/j.humpath.2008.11.005

Lee, 2004, Genetic alterations in intrahepatic cholangiocarcinoma as revealed by degenerate oligonucleotide primed PCR-comparative genomic hybridization, J Korean Med Sci, 19, 682, 10.3346/jkms.2004.19.5.682

Wu, 2013, Identification of targetable FGFR gene fusions in diverse cancers, Cancer Discov, 3, 636, 10.1158/2159-8290.CD-13-0050

Arai, 2013, FGFR2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma, Hepatology

Chen, 2009, The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma, J Hepatol, 50, 358, 10.1016/j.jhep.2008.09.015

Tannapfel, 2002, Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma, J Pathol, 197, 624, 10.1002/path.1139

Isomoto, 2007, Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing, Gastroenterology, 132, 384, 10.1053/j.gastro.2006.10.037

Tischoff, 2005, Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors, Int J Cancer, 115, 684, 10.1002/ijc.20944

Chan-On, 2013, Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers, Nat Genet, 45, 1474, 10.1038/ng.2806

Jiao, 2013, Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas, Nat Genet, 45, 1470, 10.1038/ng.2813

Park, 1999, Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line, Hepatology, 30, 1128, 10.1002/hep.510300522

Isomoto, 2005, Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells, Hepatology, 42, 1329, 10.1002/hep.20966

Kobayashi, 2005, Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells, Gastroenterology, 128, 2054, 10.1053/j.gastro.2005.03.010

Yoshikawa, 2008, Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma, Br J Cancer, 98, 418, 10.1038/sj.bjc.6604129

Endo, 2002, ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions, Hepatology, 36, 439, 10.1053/jhep.2002.34435

Nakazawa, 2005, Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers, J Pathol, 206, 356, 10.1002/path.1779

Terada, 1998, Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis, Hum Pathol, 29, 175, 10.1016/S0046-8177(98)90229-5

Miyamoto, 2011, Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma, Br J Cancer, 105, 131, 10.1038/bjc.2011.199

Radaeva, 1999, Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma, Hepatology, 29, 1453, 10.1002/hep.510290524

Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101

Tsao, 2005, Erlotinib in lung cancer – molecular and clinical predictors of outcome, N Engl J Med, 353, 133, 10.1056/NEJMoa050736

Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448

Flaherty, 2010, Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med, 363, 809, 10.1056/NEJMoa1002011

Obama, 2005, Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma, Hepatology, 41, 1339, 10.1002/hep.20718

Jinawath, 2006, Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma, Hepatology, 44, 1025, 10.1002/hep.21330

Hamilton, 2000

Nakanuma, 2010, Pathological classification of intrahepatic cholangiocarcinoma based on a new concept, World J Hepatol, 2, 419, 10.4254/wjh.v2.i12.419

Nakajima, 1988, A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma: histologic classification and modes of spreading, Hum Pathol, 19, 1228, 10.1016/S0046-8177(88)80156-4

Nakanuma, 2003, Anatomic and molecular pathology of intrahepatic cholangiocarcinoma, J Hepatobiliary Pancreat Surg, 10, 265, 10.1007/s00534-002-0729-3

Nakanuma, 2008, Pathology of peripheral intrahepatic cholangiocarcinoma with reference to tumorigenesis, Hepatol Res, 38, 325, 10.1111/j.1872-034X.2007.00312.x

Nakanuma, 2011, Pathological spectrum of intrahepatic cholangiocarcinoma arising in non-biliary chronic advanced liver diseases, Pathol Int, 61, 298, 10.1111/j.1440-1827.2011.02665.x

Vilana, 2010, Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound, Hepatology, 51, 2020, 10.1002/hep.23600

Rimola, 2009, Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma, Hepatology, 50, 791, 10.1002/hep.23071

Goodman, 2007, Neoplasms of the liver, Mod Pathol, 20, S49, 10.1038/modpathol.3800682

Cabibi, 2003, Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract, Pathol Res Pract, 199, 65, 10.1078/0344-0338-00356

Rullier, 2000, Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis, Am J Surg Pathol, 24, 870, 10.1097/00000478-200006000-00014

Valls, 2000, Intrahepatic peripheral cholangiocarcinoma: CT evaluation, Abdom Imaging, 25, 490, 10.1007/s002610000079

Kim, 2011, Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma, AJR Am J Roentgenol, 196, W205, 10.2214/AJR.10.4937

Kim, 2011, Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection, Eur J Radiol, 80, e221, 10.1016/j.ejrad.2010.09.019

Hamrick-Turner, 1992, Intrahepatic cholangiocarcinoma: MR appearance, AJR Am J Roentgenol, 158, 77, 10.2214/ajr.158.1.1309221

Fan, 1993, Intrahepatic cholangiocarcinoma: spin-echo and contrast-enhanced dynamic MR imaging, AJR Am J Roentgenol, 161, 313, 10.2214/ajr.161.2.8392787

Murakami, 1995, Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: pathologic correlation study, J Magn Reson Imaging, 5, 165, 10.1002/jmri.1880050210

Anderson, 2004, Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma, J Gastrointest Surg, 8, 90, 10.1016/j.gassur.2003.10.003

Delbeke, 1998, Evaluation of benign vs. malignant hepatic lesions with positron emission tomography, Arch Surg, 133, 510, 10.1001/archsurg.133.5.510

Kim, 2003, Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma, Eur J Nucl Med Mol Imaging, 30, 1467, 10.1007/s00259-003-1297-8

Lan, 2012, Positron emission tomography in hepatobiliary and pancreatic malignancies: a review, Am J Surg, 204, 232, 10.1016/j.amjsurg.2011.07.025

Xu, 2012, Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma: correlation with pathological examination, Br J Radiol, 85, 1029, 10.1259/bjr/21653786

Li, 2013, Dynamic enhancing vascular pattern of intrahepatic peripheral cholangiocarcinoma on contrast-enhanced ultrasound: the influence of chronic hepatitis and cirrhosis, Abdom Imaging, 38, 112, 10.1007/s00261-012-9854-x

Chong, 2012, Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI, Clin Radiol, 67, 766, 10.1016/j.crad.2012.01.004

Patel, 2000, The utility of CA 19–9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis, Am J Gastroenterol, 95, 204, 10.1111/j.1572-0241.2000.01685.x

Tamandl, 2008, Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma, Ann Surg Oncol, 15, 2787, 10.1245/s10434-008-0081-1

Uenishi, 2008, Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma, Ann Surg Oncol, 15, 583, 10.1245/s10434-007-9650-y

Karakatsanis, 2013, Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance, Mol Carcinog, 52, 297, 10.1002/mc.21864

Nishino, 2008, Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma, J Hepatol, 49, 207, 10.1016/j.jhep.2008.03.025

Schmitz, 2007, GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma, Neoplasia, 9, 159, 10.1593/neo.06796

Hann, 1998, Tumor involvement in hepatic veins: comparison of MR imaging and US for preoperative assessment, Radiology, 206, 651, 10.1148/radiology.206.3.9494482

Bach, 1996, Portal vein evaluation with US: comparison to angiography combined with CT arterial portography, Radiology, 201, 149, 10.1148/radiology.201.1.8816536

Corvera, 2008, 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer, J Am Coll Surg, 206, 57, 10.1016/j.jamcollsurg.2007.07.002

Kim, 2008, Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging, Am J Gastroenterol, 103, 1145, 10.1111/j.1572-0241.2007.01710.x

Greene, 2002, The American Joint Committee on Cancer: updating the strategies in cancer staging, Bull Am Coll Surg, 87, 13

Edge, 2010, The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM, Ann Surg Oncol, 17, 1471, 10.1245/s10434-010-0985-4

Tsai, 2010, Primary liver cancer: intrahepatic cholangiocarcinoma emerges from the shadows, Updates Surg, 62, 5, 10.1007/s13304-010-0011-1

Nathan, 2010, Staging of intrahepatic cholangiocarcinoma, Curr Opin Gastroenterol, 26, 269, 10.1097/MOG.0b013e328337c899

Yamasaki, 2003, Intrahepatic cholangiocarcinoma: macroscopic type and stage classification, J Hepatobiliary Pancreat Surg, 10, 288, 10.1007/s00534-002-0732-8

Okabayashi, 2001, A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables, Cancer, 92, 2374, 10.1002/1097-0142(20011101)92:9<2374::AID-CNCR1585>3.0.CO;2-L

Nathan, 2009, A proposed staging system for intrahepatic cholangiocarcinoma, Ann Surg Oncol, 16, 14, 10.1245/s10434-008-0180-z

Farges, 2011, AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group, Cancer, 117, 2170, 10.1002/cncr.25712

Chung, 2009, Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation, Radiographics, 29, 683, 10.1148/rg.293085729

Manfredi, 2004, Magnetic resonance imaging of cholangiocarcinoma, Semin Liver Dis, 24, 155, 10.1055/s-2004-828892

Bruix, 2005, Management of hepatocellular carcinoma, Hepatology, 42, 1208, 10.1002/hep.20933

Weber, 2001, Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes, J Am Coll Surg, 193, 384, 10.1016/S1072-7515(01)01016-X

Tan, 2008, Surgical management of intrahepatic cholangiocarcinoma – a population-based study, Ann Surg Oncol, 15, 600, 10.1245/s10434-007-9627-x

de Jong, 2011, Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment, J Clin Oncol, 29, 3140, 10.1200/JCO.2011.35.6519

Sotiropoulos, 2009, R0 liver resections for primary malignant liver tumors in the noncirrhotic liver: a diagnosis-related analysis, Dig Dis Sci, 54, 887, 10.1007/s10620-008-0408-6

Endo, 2008, Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection, Ann Surg, 248, 84, 10.1097/SLA.0b013e318176c4d3

Konstadoulakis, 2008, Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome, Surgery, 143, 366, 10.1016/j.surg.2007.10.010

Lang, 2009, Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients, J Am Coll Surg, 208, 218, 10.1016/j.jamcollsurg.2008.10.017

Nakagohri, 2008, Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma, World J Surg, 32, 2675, 10.1007/s00268-008-9778-3

Shimada, 2009, Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvement, Surgery, 145, 411, 10.1016/j.surg.2008.11.010

Nakagawa, 2005, Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma, World J Surg, 29, 728, 10.1007/s00268-005-7761-9

Choi, 2009, The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival, Ann Surg Oncol, 16, 3048, 10.1245/s10434-009-0631-1

Yamamoto, 2001, Recurrence after surgical resection of intrahepatic cholangiocarcinoma, J Hepatobiliary Pancreat Surg, 8, 154, 10.1007/s005340170039

Uenishi, 2008, Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases, J Hepatobiliary Pancreat Surg, 15, 417, 10.1007/s00534-007-1315-5

Paik, 2008, What prognostic factors are important for resected intrahepatic cholangiocarcinoma?, J Gastroenterol Hepatol, 23, 766, 10.1111/j.1440-1746.2007.05040.x

Ohtsuka, 2002, Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival, Br J Surg, 89, 1525, 10.1046/j.1365-2168.2002.02268.x

Nuzzo, 2012, Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients, Arch Surg, 147, 26, 10.1001/archsurg.2011.771

Jaeck, 2003, The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies, Ann Surg Oncol, 10, 1007, 10.1245/ASO.2003.09.903

Hyder, 2013, Recurrence after operative management of intrahepatic cholangiocarcinoma, Surgery, 153, 811, 10.1016/j.surg.2012.12.005

Takada, 1998, Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial, Hepatogastroenterology, 45, 2020

Neoptolemos, 2004, A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, N Engl J Med, 350, 1200, 10.1056/NEJMoa032295

Neoptolemos, 2012, Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs. observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial, JAMA, 308, 147, 10.1001/jama.2012.7352

Darwish Murad, 2012, Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers, Gastroenterology, 143, 88, 10.1053/j.gastro.2012.04.008

Shimoda, 2001, Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature, Liver Transpl, 7, 1023, 10.1053/jlts.2001.29419

Fu, 2011, The role of liver transplantation for intrahepatic cholangiocarcinoma: a single-center experience, Eur Surg Res, 47, 218, 10.1159/000332827

Robles, 2004, Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma, Ann Surg, 239, 265, 10.1097/01.sla.0000108702.45715.81

Sotiropoulos, 2008, Liver transplantation as a primary indication for intrahepatic cholangiocarcinoma: a single-center experience, Transplant Proc, 40, 3194, 10.1016/j.transproceed.2008.08.053

Hong, 2011, Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center, Arch Surg, 146, 683, 10.1001/archsurg.2011.116

Hong, 2011, Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma, J Am Coll Surg, 212, 514, 10.1016/j.jamcollsurg.2010.12.005

Rana, 2012, Orthotopic liver transplantation in combination with neoadjuvant therapy: a new paradigm in the treatment of unresectable intrahepatic cholangiocarcinoma, Curr Opin Gastroenterol, 28, 258, 10.1097/MOG.0b013e32835168db

Wolfe, 2010, Trends in organ donation and transplantation in the United States, 1999–2008, Am J Transplant, 10, 961, 10.1111/j.1600-6143.2010.03021.x

Maganty, 2010, Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma: outcome after liver transplantation, Dig Dis Sci, 55, 3597, 10.1007/s10620-010-1402-3

Sapisochin, 2011, Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma, Liver Transpl, 17, 934, 10.1002/lt.22307

Morise, 2010, Surgery and chemotherapy for intrahepatic cholangiocarcinoma, World J Hepatol, 2, 58, 10.4254/wjh.v2.i2.58

Lazaridis, 2011, Cholangiocarcinoma, 1032

Chen, 2010, Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients, BMC Cancer, 10, 492, 10.1186/1471-2407-10-492

Zeng, 2006, Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients, Cancer J, 12, 113

Barney, 2012, Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma, Radiat Oncol, 7, 67, 10.1186/1748-717X-7-67

Ibarra, 2012, Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors, Acta Oncol, 51, 575, 10.3109/0284186X.2011.652736

Shinohara, 2008, Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma, Int J Radiat Oncol Biol Phys, 72, 1495, 10.1016/j.ijrobp.2008.03.018

Jiang, 2010, Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and concurrent lymph node metastases, J Cancer Res Clin Oncol, 136, 1323, 10.1007/s00432-010-0783-1

Kim YI, Park JW, Kim BH, Woo SM, Kim TH, Koh YH, et al. The effect of chemoradiotherapy for unresectable advanced intrahepatic cholangiocarcinoma. International Liver Cancer Association Meeting; 2012.

O’Connor, 2011, Stereotactic body radiation therapy in the treatment of unresectable intrahepatic cholangiocarcinoma, J Clin Oncol, 29, abstr 335, 10.1200/jco.2011.29.4_suppl.335

EASL-EORTC clinical practice guidelines, 2012, Management of hepatocellular carcinoma, J Hepatol, 56, 908, 10.1016/j.jhep.2011.12.001

Hong, 2010, Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma, Semin Oncol, 37, 110, 10.1053/j.seminoncol.2010.03.002

Park, 2011, Transarterial chemoembolization vs. supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma, Clin Radiol, 66, 322, 10.1016/j.crad.2010.11.002

Edwards, 2012, Transarterial therapies for unresectable cholangiocarcinoma: a meta-analysis, J Vasc Interv Radiol, 23, S101, 10.1016/j.jvir.2011.12.298

Kiefer, 2011, Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study, Cancer, 117, 1498, 10.1002/cncr.25625

Stuebs, 2012, Developments of treatment of advanced intrahepatic cholangiocarcinoma: an analysis of systemic and local therapy modes in 57 patients, J Clin Oncol, 30, abstr 356, 10.1200/jco.2012.30.4_suppl.346

Shen, 2011, Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study, World J Surg, 35, 2083, 10.1007/s00268-011-1171-y

Aliberti, 2008, Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results, Cardiovasc Intervent Radiol, 31, 883, 10.1007/s00270-008-9336-2

Poggi, 2009, OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma, Cardiovasc Intervent Radiol, 32, 1187, 10.1007/s00270-009-9694-4

Kuhlmann, 2012, Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy, Eur J Gastroenterol Hepatol, 24, 437

Tanaka, 2002, Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma–initial experience, Eur J Radiol, 41, 42, 10.1016/S0720-048X(01)00414-4

Vogl, 2006, Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy, J Cancer Res Clin Oncol, 132, 745, 10.1007/s00432-006-0138-0

Shitara, 2008, Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma, Clin Oncol (R Coll Radiol), 20, 241, 10.1016/j.clon.2007.12.007

Ibrahim, 2008, Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study, Cancer, 113, 2119, 10.1002/cncr.23818

Saxena, 2010, Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option, Ann Surg Oncol, 17, 484, 10.1245/s10434-009-0777-x

Hoffmann, 2012, Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival, Cardiovasc Intervent Radiol, 35, 105, 10.1007/s00270-011-0142-x

Chiou, 2005, Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma, Kaohsiung J Med Sci, 21, 304, 10.1016/S1607-551X(09)70125-1

Carrafiello, 2010, Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience, Cardiovasc Intervent Radiol, 33, 835, 10.1007/s00270-010-9849-3

Kim, 2011, Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern–correlation with clinicopathologic findings, Radiology, 260, 148, 10.1148/radiol.11101777

Haidu, 2012, Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective study, Cardiovasc Intervent Radiol, 35, 1074, 10.1007/s00270-011-0288-6

Giorgio, 2011, Radiofrequency ablation for intrahepatic cholangiocarcinoma: retrospective analysis of a single centre experience, Anticancer Res, 31, 4575

Fu, 2012, Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma, J Vasc Interv Radiol, 23, 642, 10.1016/j.jvir.2012.01.081

Kamphues, 2010, Recurrent intrahepatic cholangiocarcinoma: single-center experience using repeated hepatectomy and radiofrequency ablation, J Hepatobiliary Pancreat Sci, 17, 509, 10.1007/s00534-009-0256-6

Livraghi, 2012, Complications of microwave ablation for liver tumors: results of a multicenter study, Cardiovasc Intervent Radiol, 35, 868, 10.1007/s00270-011-0241-8

Glimelius, 1996, Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer, Ann Oncol, 7, 593, 10.1093/oxfordjournals.annonc.a010676

Sharma, 2010, Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study, J Clin Oncol, 28, 4581, 10.1200/JCO.2010.29.3605

Eckel, 2007, Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials, Br J Cancer, 96, 896, 10.1038/sj.bjc.6603648

Valle, 2009, Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study, Br J Cancer, 101, 621, 10.1038/sj.bjc.6605211

Valle, 2010, Cisplatin plus gemcitabine vs. gemcitabine for biliary tract cancer, N Engl J Med, 362, 1273, 10.1056/NEJMoa0908721

Okusaka, 2010, Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan, Br J Cancer, 103, 469, 10.1038/sj.bjc.6605779

Oh, 2011, Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness, Invest New Drugs, 29, 1066, 10.1007/s10637-010-9417-3

Bekaii-Saab, 2011, Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers, J Clin Oncol, 29, 2357, 10.1200/JCO.2010.33.9473

Malka, 2009, A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO trial, J Clin Oncol, 27, 4520, 10.1200/jco.2009.27.15_suppl.4520

Moehler, 2011, A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib vs. gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract cancer: first safety and efficacy data, J Clin Oncol, 29, abstr 4077, 10.1200/jco.2011.29.15_suppl.4077

Ko, 2006, Polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR C677T) and thymidylate synthase enhancer region (TSER) as a risk factor of cholangiocarcinoma in a Korean population, Anticancer Res, 26, 4229

Marahatta, 2006, Polymorphism of glutathione S-transferase omega gene and risk of cancer, Cancer Lett, 236, 276, 10.1016/j.canlet.2005.05.020

Hoblinger, 2009, Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer, Digestion, 80, 36, 10.1159/000212990

Wadsworth, 2011, Genetic factors in the pathogenesis of cholangiocarcinoma, Dig Dis, 29, 93, 10.1159/000324688

Melum, 2008, Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms, Hepatology, 47, 90, 10.1002/hep.21964

Huang, 2008, Selected base excision repair gene polymorphisms and susceptibility to biliary tract cancer and biliary stones: a population-based case-control study in China, Carcinogenesis, 29, 100, 10.1093/carcin/bgm247

Sakoda, 2006, Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China, Carcinogenesis, 27, 1251, 10.1093/carcin/bgi314

Mihalache, 2011, Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma, Aliment Pharmacol Ther, 33, 389, 10.1111/j.1365-2036.2010.04534.x

Glimelius, 1998, Bolus injection (2–4min) vs. short-term (10–20min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group, Eur J Cancer, 34, 674, 10.1016/S0959-8049(97)10055-7

Kornek, 2004, Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial, Ann Oncol, 15, 478, 10.1093/annonc/mdh096

Ducreux, 2005, A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial, Eur J Cancer, 41, 398, 10.1016/j.ejca.2004.10.026

Rao, 2005, Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer, Br J Cancer, 92, 1650, 10.1038/sj.bjc.6602576